Amgen Assist 360
Amgen
The provided page content describes the prescription medication KYPROLIS® (carfilzomib) for multiple myeloma, including its approved uses, safety information, and patient testimonials. There is no information about a patient travel assistance grant, financial support, or application details on this page.
- Covers
- financial assistance
- Enrollment cycle
- unknown
Eligibility
The program is available to U.S. patients with private or commercial insurance who are prescribed KYPROLIS for relapsed or refractory multiple myeloma. There is no income eligibility requirement for the co-pay program, which can reduce out-of-pocket costs to as little as $0 per dose.
Apply
Application goes directly to Amgen. RxCopays does not receive compensation.
Go to application →Rare-disease support beyond financial help
This grant covers 10 rare conditions. For specialists, clinical trials, and patient communities, our sister site UniteRare.org has in-depth pages: